Delve into the NCCN guidelines and contemporary treatments for desmoid tumors and explore the multidisciplinary approach, limitations, and current standard care options for enhanced patient outcomes.
Experts discuss the controversial role of gene expression patterns in Desmoid tumor treatment decisions, highlighting challenges and potential impact on personalized care.
Experts discuss the role of multidisciplinary teams, gene expression patterns, rare disease drug designation, and education gaps in managing Desmoid tumors, emphasizing the need for comprehensive care and precision medicine.
Experts provide insights on recent ICD-10 code availability for desmoid tumors, its implications on diagnosis, treatment, and coverage decisions, as well as the significance for research, patient care, and health care management strategies.
Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence.